Biorithm

We’re honored to be selected as one of  150 Top Innovators and will be showcasing our femom(TM) maternal fetal monitoring technology at the New England Venture Summit on December 11th. The Summit connects founders of the hottest venture backed, emerging and early-stage companies with an exclusive audience of venture capitalists, corporate investors, private investors, investment bankers, and strategic partners. Our CEO Jenny Hoffmann, PhD will present at the event. For more info on the event visit https://lnkd.in/eitmsD7m #innovation #startup #nevs24 #NewEnglandVentureSummit #youngstartupventures

Biorithm was recently featured on CNBC regarding our mission to revolutionize maternity care. Let’s look at the numbers on the current state of care: 2.3 million neonatal deaths occurred in 2022 A maternal death occurred every two minutes in 2020 6500 newborn deaths occur every day As co-founder Amrish Nair says “Biorithm is about ending preventable pregnancy complications by developing remote monitoring technologies, thus improving access and enabling more patients to receive high quality care.” The link for the full video is in the comments.

Biorithm was recently featured in an interview with CEO Jenny Hoffmann, PhD and host Jeff Freedman on the Brand Heart podcast! Check out the heart behind our mission to end preventable pregnancy complications at https://lnkd.in/d_HQ5xrq

Founded and led by engineers, Biorithm empowers women to make a difference in the world.

Biorithm celebrates CEO Jenny Hoffmann, PhD presenting our exciting product and accomplishments at LSI Europe!

Exciting News! Biorithm has been selected as a semifinalist in the 2024 Women’s Health Tech Challenge! This opportunity allows us to showcase Femom, aimed to end preventable pregnancy complications, in front of a panel of judges and leaders in women’s health innovation. A big thank you to the HITLAB team for this incredible opportunity to elevate innovation in women’s health! Register below for the pitch date on October 4th: https://lnkd.in/e9rKpW7D #WHTChallenge2024 #WomensHealthInnovation #TechForGood #InnovationInHealth #Semifinalist

Biorithm (LSI Europe ‘24 Innovator) has a mission to end preventable pregnancy complications while reshaping how pregnancy care is delivered. The company is developing a comprehensive maternity care platform, Femom, to improve perinatal outcomes. The Femom platform merges clinical-grade fetal monitor data with patient reported symptoms and more traditional biometrics (e.g., glucose, blood pressure) to provide clinicians with new insights into the health of the mother and baby. Biorithm has reached significant milestones, including: • Raised a $3.5M in Series A1 funding round co-led by Adaptive Capital Partners and SEEDS Capital (December 2023) • Appointed Jenny Hoffman as CEO (July 2024) • Has four papers published in Tier 1 journals • Two ongoing home-based studies in the US and UK to demonstrate a new maternity care standard. • Currently has 600 patients enrolled worldwide We’re excited to announce that CEO, Jenny Hoffmann, PhD has been selected to present Biorithm at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Jenny and learn more about Biorithm.

The Biorithm team was together in Singapore last week! We look forward to some significant milestones in the next year for this amazing team!

🙌 We congratulate the team at St George's University Hospitals NHS Foundation Trust's on their publication on emerging technology for fetal monitoring. 🚀 We are excited to be part of the modernization of pregnancy management and fetal heart rate monitoring in offering a solution that can advance fetal medicine and end preventable pregnancy complications. #biorithm #femom #fetalmedicine #femtech #womenshealth

Biorithm is excited to welcome Jenny Hoffmann, PhD as our CEO! For more information, please see the article. https://lnkd.in/edDrZ3Pz